The 2021 Cellicon Valley Symposium is presented by Penn’s Abramson Cancer Center and Children’s Hospital of Philadelphia. The virtual event will be held Thursday May 6th and Friday May 7th with a focus on novel strategies and future developments in the field of CAR T cell therapy. By bringing together medical professionals, academic researchers, and industry innovation all participants will get an opportunity to see the future of cell and gene therapy in action.
Kytopen’s Co-Founder and CTO Cullen Buie will be presenting in Track 3: Pre-clinical / Manufacturing (May 6th ) on our Flowfect® technology where he will be discussing the benefits of electro-mechanical transfection. The Flowfect® technology is a flexible, complete solution for non-viral cell engineering that integrates the discovery, development, and manufacturing of cell and gene therapeutics. The platform speeds therapies from the clinic to commercial use by enabling cell engineering without compromising functionality or viability.
With the University of Pennsylvania, ranking 1st among global universities for CAR-T cell patents according to Nature, leading this symposium it is sure to be a great source of learning and networking. For more information on the agenda and to register please see https://www.med.upenn.edu/cellicon2021/.
Kytopen, an MIT spin-out company, is a transformative biotechnology company offering non-viral delivery that links the discovery, development and manufacturing of engineered cell therapies. It has recently made its Flowfect® Tx system available to select bio-pharma partners and collaborators to accelerate their engineering cell therapy production.